Trial Condition(s):

Vaginal candidiasis, Bacterial vaginosis, Trichomonal vaginitis

Observational program Neo-Penotran® Forte

Bayer Identifier:

15511

ClinicalTrials.gov Identifier:

NCT01335373

EudraCT Number:

Not Available

Study Completed

Trial Purpose

Vaginitis is the most common gynecologic diagnosis in the primary care setting. In approximately 90 percent of affected women, this condition occurs secondary to bacterial vaginosis, vulvovaginal candidiasis, trichomoniasis or mixed infection.
Neo-Penotran Forte is registered for treatment of these most common vaginal infections. Efficacy and safety of this product is already established, and this observational study was designed to learn more about practical use of Neo-Penotran® Forte in real life setting.

Inclusion Criteria
- Patients older than 18 years with previously taken decision of their gynecologist to prescribe Neo-Penotran Forte according to registered indications, and microbiological tests were performed.
Exclusion Criteria
- Presence of contraindications according to package insert.

Trial Summary

Enrollment Goal
13024
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Neo-Penotran Forte(Metronidazole/Miconazole, BAY86-5276)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Kazakhstan

Status
Completed
 

Trial Design